RenovoRx, Inc. Schedules 2024 Annual Meeting of Stockholders
Ticker: RNXT · Form: DEF 14A · Filed: Apr 30, 2024 · CIK: 1574094
| Field | Detail |
|---|---|
| Company | Renovorx, INC. (RNXT) |
| Form Type | DEF 14A |
| Filed Date | Apr 30, 2024 |
| Risk Level | low |
| Pages | 16 |
| Reading Time | 19 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: RenovoRx, RNXT, Annual Meeting, Proxy Statement, Stockholder Vote
TL;DR
<b>RenovoRx, Inc. invites stockholders to its 2024 Annual Meeting on June 6, 2024, recommending a 'FOR' vote on all proposals.</b>
AI Summary
RenovoRx, Inc. (RNXT) filed a Proxy Statement (DEF 14A) with the SEC on April 30, 2024. RenovoRx, Inc. will hold its 2024 Annual Meeting of Stockholders on June 6, 2024, at 9:00 a.m. Pacific Time. The meeting will take place at 1440 O'Brien Drive, Menlo Park, California. Stockholders of record as of April 11, 2024, are entitled to vote. Proxy materials and the 2023 Annual Report are available on the company's website. The Board of Directors unanimously recommends voting 'FOR' all proposals.
Why It Matters
For investors and stakeholders tracking RenovoRx, Inc., this filing contains several important signals. The annual meeting is a key event for shareholders to influence company direction through voting on proposals. The company is seeking shareholder approval for matters deemed by the Board to be in the best interests of the company and its stockholders.
Risk Assessment
Risk Level: low — RenovoRx, Inc. shows low risk based on this filing. The filing is a routine proxy statement for an annual meeting, containing no new material financial or operational information that would significantly alter the risk profile.
Analyst Insight
Review the proposals to be voted on at the annual meeting to understand management's priorities and potential strategic shifts.
Key Numbers
- 2024 — Annual Meeting Year (2024 Annual Meeting of Stockholders)
- June 6 — Annual Meeting Date (Thursday, June 6, 2024)
- 9:00 a.m. Pacific Time — Annual Meeting Time (9:00 a.m., Pacific Time)
- April 11, 2024 — Record Date (Stockholders of record... at the close of business on April 11, 2024)
- 2023 — Annual Report Year (2023 Annual Report)
Key Players & Entities
- RenovoRx, Inc. (company) — Name of Registrant
- June 6, 2024 (date) — Date of Annual Meeting
- April 11, 2024 (date) — Record Date for stockholders
- April 30, 2024 (date) — Date proxy materials are made available
- May 3, 2024 (date) — Date proxy materials are mailed
FAQ
When did RenovoRx, Inc. file this DEF 14A?
RenovoRx, Inc. filed this Proxy Statement (DEF 14A) with the SEC on April 30, 2024.
What is a DEF 14A filing?
A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by RenovoRx, Inc. (RNXT).
Where can I read the original DEF 14A filing from RenovoRx, Inc.?
You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by RenovoRx, Inc..
What are the key takeaways from RenovoRx, Inc.'s DEF 14A?
RenovoRx, Inc. filed this DEF 14A on April 30, 2024. Key takeaways: RenovoRx, Inc. will hold its 2024 Annual Meeting of Stockholders on June 6, 2024, at 9:00 a.m. Pacific Time.. The meeting will take place at 1440 O'Brien Drive, Menlo Park, California.. Stockholders of record as of April 11, 2024, are entitled to vote..
Is RenovoRx, Inc. a risky investment based on this filing?
Based on this DEF 14A, RenovoRx, Inc. presents a relatively low-risk profile. The filing is a routine proxy statement for an annual meeting, containing no new material financial or operational information that would significantly alter the risk profile.
What should investors do after reading RenovoRx, Inc.'s DEF 14A?
Review the proposals to be voted on at the annual meeting to understand management's priorities and potential strategic shifts. The overall sentiment from this filing is neutral.
How does RenovoRx, Inc. compare to its industry peers?
RenovoRx, Inc. operates in the pharmaceutical preparations industry, focusing on developing and commercializing therapies.
Are there regulatory concerns for RenovoRx, Inc.?
The filing is a standard proxy statement (DEF 14A) under the Securities Exchange Act of 1934, detailing information for the annual shareholder meeting.
Industry Context
RenovoRx, Inc. operates in the pharmaceutical preparations industry, focusing on developing and commercializing therapies.
Regulatory Implications
The filing is a standard proxy statement (DEF 14A) under the Securities Exchange Act of 1934, detailing information for the annual shareholder meeting.
What Investors Should Do
- Review the proposals presented in the proxy statement for the 2024 Annual Meeting.
- Ensure voting rights are exercised by the record date of April 11, 2024.
- Access the 2023 Annual Report for financial and operational performance insights.
Key Dates
- 2024-06-06: 2024 Annual Meeting of Stockholders — Key date for shareholder voting and company decisions.
- 2024-04-11: Record Date — Determines which stockholders are eligible to vote at the annual meeting.
- 2024-04-30: Proxy Materials Availability — Date proxy materials and 2023 Annual Report are made available to stockholders.
- 2024-05-03: Proxy Materials Mailing — Date proxy materials are intended to be mailed to stockholders.
Year-Over-Year Comparison
This filing is a routine proxy statement for the annual meeting and does not represent a change from previous filings in terms of new financial data or operational updates.
Filing Stats: 4,847 words · 19 min read · ~16 pages · Grade level 11.5 · Accepted 2024-04-30 16:30:13
Filing Documents
- formdef14a.htm (DEF 14A) — 487KB
- formdef14a_001.jpg (GRAPHIC) — 3KB
- 0001493152-24-017244.txt ( ) — 493KB
Executive Compensation
Executive Compensation 24
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 34 Other Information 35 You may vote at the Annual Meeting, via the Internet or by mail (see attached proxy card) Internet: https://annualgeneralmeetings.com/rnxt2024 2 4546 El Camino Real, Suite B1 Los Altos, CA 94022 PROXY FOR THE ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON JUNE 6, 2024 This proxy statement (the “ Proxy Statement ”) and our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (the “ 2023 Annual Report ”) and, together with the Proxy Statement, the “proxy materials”) are being furnished by and on behalf of the board of directors (the “ Board of Directors ”) of RenovoRx, Inc. (the “ Company ,” “ we ,” “ us ,” or “ our ”), in connection with our 2024 Annual Meeting of Stockholders (the “ Annual Meeting ”). This Notice of Annual Meeting and Proxy Statement are first being mailed on or about May 3, 2024. GENERAL INFORMATION ABOUT THE ANNUAL MEETING AND VOTING QUESTIONS AND ANSWERS When and where will the Annual Meeting be held? The Annual Meeting will be held on Monday, June 6, 2024 at 9:00 a.m. Pacific Time at 1440 O’Brien Drive, Menlo Park, California 94025. What is the purpose of the Annual Meeting? The purpose of the Annual Meeting is to vote on the following items described in this Proxy Statement: Proposal No. 1 : Election of six members of the Board of Directors (all of whom are currently serving as directors) to serve until our 2025 Annual Meeting of Stockholders and until their successors are duly elected and qualified, subject to their earlier death, resignation or removal. In addition, in their discretion, the proxies if designated as such are authorized to vote upon such other business as may properly come before the Annual Meeting or any continuation, postponement or